Category: cannabinoid

  • Jazz breaks ground on $100m UK plant for cannabinoid drugs

    Jazz Pharma has started construction of a manufacturing facility in the UK that will be used to manufacture cannabinoid drugs from its recently acquired GW Pharma subsidiary. The 60,000 sq. ft. facility at Kent Science Park (KSP) in Sittingbourne is due to open in 2024, and when fully operational will create more than 100 new […]

  • Trial of Jazz’ cannabis drug in glioblastoma will start next year

    An investigator-led trial of Jazz Pharma’s cannabis extract-based drug Sativex in glioblastoma – an aggressive form of brain cancer – will get underway in the UK next year. The three-year phase 2 trial will be carried out by researchers at Leeds University led by professor of clinical oncology and neuro-oncology Susan Short, and see if […]

  • 13 of the most commonly asked questions about Glioblastoma multiforme, Answered

    What is Glioblastoma Multiforme? Glioblastoma multiforme (GBM) (also called glioblastoma) is a fast-growing type of gliomas, which are the most common form of primary tumors of the central nervous system (CNS). These develop from star-shaped glial cells (astrocytes and oligodendrocytes) responsible for providing nourishment to the nerve cells within the brain. Often referred to as […]

  • Medical Marijuana: Is it a blessing in disguise or a curse for humanity?

    An influx of companies, the launch of pipeline therapies, and the legalization of marijuana/ cannabis are the major drivers of the medical marijuana market. Cannabis, popularly known as Marijuana, is the most commonly used illicit drug after alcohol. More than 150 Million people regularly smoke marijuana. Approximately 11.8 Million young adult American populations consumed marijuana […]